---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039068"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T03:45:26.359280+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# RxSight Q2 revenue $20.8M (+83% YoY); raises FY2023 guidance; pays off $40M debt

## Summary
- Q2 revenue $20.8M (+83% YoY); net loss $(13.8)M vs $(16.7)M last year.
- Raised FY2023 revenue guidance to $81-86M (prior $79-84M); gross margin 58-60%.
- LAL procedure volumes 12,622 (+134% YoY); LDD installed base 523 (+78% YoY).
- Paid off $40M debt in Q2 and early Q3, eliminating ~$5.6M annual interest expense.
- Raised ~$31.3M net from ATM in Q2 and early Q3 to fund debt repayment.

## SEC filing metadata
- accession: 0000950170-23-039068
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000095017023039068/0000950170-23-039068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000095017023039068/rxst-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039068
- JSON: https://secwatch.observer/filing/0000950170-23-039068.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039068.txt

## Key facts
- Earnings Releases
  RxSight, Inc. reported three and six months ended June 30, 2023 results: revenue $20.8 million, net income $(13.8) million, EPS $(0.40) per basic and diluted share. Guidance raised.
  - Period: three and six months ended June 30, 2023
  - Revenue: $20.8 million
  - Net income: $(13.8) million
  - EPS: $(0.40) per basic and diluted share
  - Guidance: raised
  - Result: reported results
  source text: following cataract surgery, today reported financial results for the three and six months ended June 30, 2023. Key Quarterly Highlights • Reported second quarter 2023 revenue of $20.8 million, an increase of 83% compared to the second quarter of 2022, reflecting: • The sale of 67 Light Delivery Devices (LDDTMs), representing a 37% increase in unit sales compared to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1111485/000095017023039068/0000950170-23-039068-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.